JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study

  • 0Department of Endocrinology and Diabetology, CHU Dijon 21000 Dijon, France.
Diabetes Research and Clinical Practice +

|

February 3, 2025

|

February 3, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Glucagon-like peptide-1 receptor agonists (GLP1-RA) significantly reduced intramyocardial fat in type 2 diabetes patients. This finding suggests a specific effect on myocardial steatosis, potentially contributing to cardiovascular benefits.

Area Of Science

  • Cardiology
  • Metabolic Diseases
  • Pharmacology

Background

  • Type 2 diabetes (T2D) is associated with increased intramyocardial fat, a potential contributor to cardiovascular complications.
  • Glucagon-like peptide-1 receptor agonists (GLP1-RA) have demonstrated cardioprotective effects in T2D patients, but the underlying mechanisms are not fully understood.

Purpose Of The Study

  • To investigate the impact of GLP1-RA treatment on intramyocardial triglyceride content in patients with type 2 diabetes.
  • To explore whether changes in intramyocardial fat correlate with improvements in glycemic control and body mass index.

Main Methods

  • A monocentric cohort study involving T2D patients initiating GLP1-RA therapy.
  • Cardiac magnetic resonance imaging (MRI) and nuclear magnetic resonance (NMR) spectroscopy were used at baseline and six months to assess intramyocardial triglyceride levels and cardiac parameters.
  • Statistical analysis included Student's t-test or sign test to evaluate changes.

Main Results

  • A significant reduction in relative intramyocardial triglyceride levels was observed after six months of GLP1-RA treatment (mean Δr = -26%, p=0.003).
  • Concomitant significant decreases were noted in glycated hemoglobin (HbA1c), body mass index (BMI), and left ventricular mass.
  • No significant correlation was found between the reduction in intramyocardial triglyceride content and the changes in HbA1c or BMI.

Conclusions

  • GLP1-RA treatment leads to a significant decrease in intramyocardial triglyceride content in T2D patients.
  • The observed reduction in myocardial steatosis appears independent of glycemic control and BMI changes, suggesting a direct effect of GLP1-RA.
  • This specific effect on myocardial fat may underlie the cardiovascular benefits associated with GLP1-RA therapy in T2D.

Keywords:

Related Concept Videos

Glucagon-like Receptor Agonists 01:24

292

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors 01:23

164

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Overview of Lipid Metabolism 01:24

969

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...